Stemina Biomarker Discovery

12 articles about Stemina Biomarker Discovery

• Stemina’s Human Cell-Based devTOX quickPredict Assay Able to Predict Developmental Toxicity Potential of Nicotine-Containing Products

  12/17/2020

  Stemina’s Human Cell-Based devTOX quick Predict Assay Able to Predict Developmental Toxicity Potential of Nicotine-Containing Products New research study published in the scientific journal Current Research in Toxicology

• Unique Metabolic Signatures Associated with Autism Spectrum Disorder (ASD) Detect More than 50% of individuals with ASD in Children’s Autism Metabolome Project (CAMP)

  6/18/2020

  New Findings from the CAMP Study, a 1,102 Subject Study of the Metabolism of Children with ASD, Published in Autism Research

• Stemina’s Human Stem Cell-Based Test Demonstrates Potential to Predict Which Drugs and Chemicals Cause Birth Defects

  3/3/2020

  EPA’s ToxCast™ evaluation of the developmental toxicity risk of 1,065 compounds using Stemina’s devTOX quickPredict test (devTOXqP) published in Toxicological Sciences

• Stemina’s Human Induced Pluripotent Stem Cell Test Predicts Drug Cardiovascular Toxicity

  2/20/2020

  Feb. 20, 2020 13:00 UTC Study reports on the first human cellular and metabolomics-based test for the evaluation of drugs for cardiotoxic effects MADISON, Wis.--( BUSINESS WIRE )-- Stemina Biomarker Discovery, Inc., today announced study results showing the high performance of the company’s Cardio quick Predict test in identifying cardiotoxic effects for a large number of well-characterized drugs. These results suggest the drug screening test could provide drug developers

• NeuroPointDX Announces Commercialization of First Objective Blood Test to Aid Earlier Diagnosis of Autism Spectrum Disorder

  11/1/2018

  NeuroPointDx, a division of Stemina Biomarker Discovery, today announced the commercial launch of its NPDX AA test, which identifies metabolic subtypes associated with autism spectrum disorder (ASD).

• Stemina Biomarker Discovery Announces Rebranding Of Its Diagnostics Business, New Board Member Kevin Krenitsky, MD, And Progress From Its Clinical Study

  5/10/2016

• Stemina Biomarker Discovery Launches Largest Ever Clinical Study Of Metabolism Of Children With Autism

  9/23/2015

• Metabolon Files Patent Infringement Lawsuit Against Stemina Biomarker Discovery

  8/27/2012

• ILS and Stemina Biomarker Discovery Announce Exclusive Partnership for Human Stem Cell Based Toxicology Testing

  11/1/2011

• CIT and Stemina Biomarker Discovery Announce Partnership in Europe for Stem Cell Based Toxicology Testing

  2/17/2011

• Agilent Technologies Inc. and Stemina Biomarker Discovery Announce Efforts to Accelerate Stem Cell Metabolite Biomarker Discovery

  5/25/2010

• California Stem Cell, Inc. and Stemina Biomarker Discovery Announce Collaboration to Validate Effectiveness of Human Embryonic Stem Cell-Derived Cardiomyocyte Progenitors for Use in Predictive Toxicology

  9/17/2009